Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04279847 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
A Phase 1 study of Myelodysplastic Syndrome and Myelofibrosis, sponsored by Incyte Corporation.
- Active
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
- 20
- Study locations
NCT04279847: Active Phase 1 study of Myelodysplastic Syndrome and Myelofibrosis, sponsored by Incyte Corporation.
NCT04279847 is a Phase 1 study of Myelodysplastic Syndrome and Myelofibrosis that is active but no longer recruiting, run by Incyte Corporation. The registered enrollment target is 140 participants, below the 206-participant average among 134 other Myelodysplastic Syndrome trials with a reported enrollment target (32% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04279847, a Phase 1 study of Myelodysplastic Syndrome and Myelofibrosis, is active but no longer recruiting, sponsored by Incyte Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of INCB057643 as monotherapy or combination with ruxolitinib for participants with myelofibrosis (MF) and other myeloid neoplasms.
Primary Outcome
Defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug monotherapy and in combination with ruxolitinib.
Conditions Studied
Interventions
- DRUG Ruxolitinib
- DRUG INCB057643
Study Locations (20)
New York
- Nyu Langone Health - Long Island Hospital - Mineola
- Nyu Langone Laura and Isaac Perlmutter Cancer Center - New York
- Weill Medical College of Cornell University - New York
Texas
- Texas Oncology-Baylor Sammons Cancer Center - Dallas
- Md Anderson Cancer Center - Houston
- Oncology Consultants - Houston
Ohio
- University of Cincinnati Cancer Institute - Cincinnati
- Ohio State University - Columbus
Alabama
- University of Alabama At Birmingham - Birmingham
Colorado
- University of Colorado Cancer Center - Aurora
Florida
- University of Miami Sylvester Comprehensive Cancer Center - Miami
Georgia
- Emory University-Winship Cancer Institute - Atlanta
Iowa
- University of Iowa Hospital and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2021-02-23 |
| Est. Completion | 2027-04-30 |
| Phase | Phase 1 |
What the registry record for NCT04279847 still lists
NCT04279847 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 206-participant average among 134 other Myelodysplastic Syndrome trials with a reported enrollment target (32% lower).
The record links to 7 conditions, with Myelodysplastic Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Ruxolitinib is the first listed.
NCT04279847 names 20 study sites across 15 states, led by New York, Texas, Ohio.
Frequently Asked Questions
What is clinical trial NCT04279847 about?
NCT04279847 is a clinical study titled "Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms". The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of INCB057643 as monotherapy or combination with ruxolitinib for participants with myelofibrosis (MF) and other myeloid neoplasms.
What is the current status of trial NCT04279847?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2021-02-23. Estimated completion is 2027-04-30.
What conditions does trial NCT04279847 study?
This clinical trial studies the following conditions: Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, ET (Essential Thrombocythemia), Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome.
What interventions are being tested in trial NCT04279847?
The interventions under investigation include: Ruxolitinib (DRUG), INCB057643 (DRUG).
Who is sponsoring clinical trial NCT04279847?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04279847 being conducted?
This trial has 20 study locations across Alabama, Colorado, Florida, Georgia, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04279847's enrollment target sits among peer trials
140 24th of 134 higher than 110 of 134 other Myelodysplastic Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myelodysplastic Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
RECRUITING · Phase 1
-
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
RECRUITING · Phase 1
-
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
- NCT02507141 · 140 participants
Reflectance Confocal Microscopy of Oral Cancers in Vivo: a Preliminary Trial Comparing Intra-oral Imaging With Pathology
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI